Description
Becton, Dickinson and Company: How Are They Achieving Growth in Pharmaceutical Systems through Biologics and Biosimilars!
Becton, Dickinson and Company (BD), a global medical technology company, recently updated investors in their third quarter fiscal 2024 earnings presentation. Throughout the quarter, BD showcased steady corporate performance with some aids and obstacles highlighted during the financial period. Tom Polen, Chairman, CEO, and President, and CFO Chris DelOrefice conducted the earnings presentation.
Our Report Structure:
⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures
Want unlimited access to our reports? Purchase our $99 annual subscription!
